menu
    • menu

    Company profile for AffyImmune Therapeutics

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Willow Birch Pharma delivers trusted, high-quality APIs nationwide with unmatched service, compliance, and competitive value.

    Virtual Booth

    Contact Supplier

    AMI Lifesciences is Driven by Chemistry. Powered by People.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    AffyImmune is a clinical stage biotechnology company focused on developing technologies that expand the utility and improve the safety and efficacy of cell-based immunotherapy for cancer. AffyImmune’s core focus is on developing CAR T cells effective in treating solid tumors, which account for 90% of all cancer fatalities. Our Phase I clinical trial of our lead compound in patients with anaplastic or refractory thyroid cance...
    AffyImmune is a clinical stage biotechnology company focused on developing technologies that expand the utility and improve the safety and efficacy of cell-based immunotherapy for cancer. AffyImmune’s core focus is on developing CAR T cells effective in treating solid tumors, which account for 90% of all cancer fatalities. Our Phase I clinical trial of our lead compound in patients with anaplastic or refractory thyroid cancer is now enrolling patients. AffyImmune was founded in 2016 on the basis of research and technologies developed at Harvard Medical School and Weill Cornell Medical College.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    AffyImmune TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    22 Strathmore Road Natick, MA 01760 (617) 699-1965
    Telephone
    Telephone
    (617) 699-1965
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://affyimmune.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    DCAT Week

    DCAT Week

    Not Confirmed

    envelop Contact Supplier

    DCAT Week

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    AffyImmune to Present ICAM-1 CAR T Therapy AIC100 at AACR 2025
    AffyImmune to Present ICAM-1 CAR T Therapy AIC100 at AACR 2025

    28 Apr 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/affyimmune-announces-plenary-oral-presentation-on-icam-1-directed-car-t-therapy-aic100-at-aacr-2025-302439754.html

    PR NEWSWIRE
    28 Apr 2025
    Share Share
    AffyImmune Appoints Deyaa Adib, MD as Chief Medical Officer
    AffyImmune Appoints Deyaa Adib, MD as Chief Medical Officer

    25 Nov 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/affyimmune-appoints-deyaa-adib-md-as-chief-medical-officer-302315364.html

    PR NEWSWIRE
    25 Nov 2024
    Share Share
    AffyImmune Adds Drs Rutter And Nieva To Board Of Directors
    AffyImmune Adds Drs Rutter And Nieva To Board Of Directors

    23 Sep 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240923490979/en

    BUSINESSWIRE
    23 Sep 2024
    Share Share
    AffyImmune Gets FDA RMAT Designation For AIC100 In Thyroid Cancer
    AffyImmune Gets FDA RMAT Designation For AIC100 In Thyroid Cancer

    23 Jul 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240723305679/en

    BUSINESSWIRE
    23 Jul 2024
    Share Share
    AffyImmune Appoints Dr. Daniel Janse as Chief Executive Officer
    AffyImmune Appoints Dr. Daniel Janse as Chief Executive Officer

    15 Jul 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240715681945/en

    BUSINESSWIRE
    15 Jul 2024
    Share Share
    Affyimmune Complete Anaplastic: Thyroid Cancer Response Confirmed
    Affyimmune Complete Anaplastic: Thyroid Cancer Response Confirmed

    23 May 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240523653892/en

    BUSINESSWIRE
    23 May 2024
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search